Travere’s Sparsentan Faces Slower Uptake Due To Liver Monitoring Requirement

Firm Thinks Unmet Need Will Ensure Commercial Success

 
• By Alaric DeArment
  
Travere said its PDUFA date for sparsentan, originally 17 November, would be extended by three months • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business